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*THE FIRST BAGSHAWE LECTURE
Towards generating cytotoxic agents at cancer sites
K.D. Bagshawe
Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital, London W6 8RF, UK.
Summary Several years of experience have now accumulated in the targeting of anti-cancer agents so that we
can take stock, identify problems and look for ways round them. Three major obstacles seem to limit present
approaches. These are heterogeneity in the distribution of target molecules within the cancer cell population,
the pharmacokinetic characteristics of macromolecules and host antibody response to foreign protein. An
approach which we have been investigating uses antibodies or other vectors to carry enzymes which have no
close human homologue to tumour sites. After clearing residual enzyme activity from the blood by one of
several possible techniques, a relatively non-toxic prodrug is given. This prodrug is a substrate for the tumour
located enzyme which results in the generation of a highly toxic molecule able to penetrate the tumour mass
and cross cell membranes. Genetic engineering methods now offer the prospect of human immunoglobulins
with tumour binding and catalytic sites having the potential to minimise host response. Whether this can be
achieved depends on having antibodies with adequate specificity and our ability to develop enzyme-prodrug
systems with the required characteristics. Early results encourage us to think progress can be made in this
direction.
First, I want to thank the Association of Cancer Physicians
for the great honour of calling this 'The Bagshawe Lecture'.
Although the subject of my talk is perhaps too new yet to be
controversial, perhaps I can express the wish that future
Bagshawe lecturers will not shrink from controversy or
unwheeling contemporary bandwagons. At one stage in
preparing this talk I had in mind a critique of the contem-
porary approach to drug resistance but there would have
been an excess of questions and few answers. So I have
turned from attempted demolition to an area where there are
prospects for construction.
Introduction to targeting
The objective of targeting is the systemic delivery of thera-
peutic agents to sites of action so as to achieve a favourable
differential in drug concentration x time between target and
non-target sites. Within the concept of targeting is the
implication that the delivery function and the effector func-
tion of a pharmaceutical agent are distinctive properties. The
present study shows that these two functions may be
expressed on different molecules which interact.
The development of targeting agents owes much to the
availability of a series of test systems which proceed through
in vitro studies on cell lines, immunohistochemical studies of
normal human tissues and tumours, through human xeno-
grafts in nude mice or rats for both imaging and therapeutic
studies and as a final pre-therapeutic study, diagnostic
immunoscintigraphy in patients.
Targets
To begin we need to consider the targets. In cancer appli-
cations our target is a subset of cells dispersed within many
different subsets. Our ability to identify the cancer subset
and thus achieve selective delivery depends on identifying
specific macromolecules. So the target may be an antigen, or
a unique epitope or a receptor. There is the possibility of
using small vectors such as growth factors, or protein or
peptide hormones (Hattner et al., 1984; Krenning et al.,
1989) but most studies so far have used antibody or
antibody fragments directed at tumour associated antigens
because these have perhaps more general applicability.
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Except for the idiotypic determinants on the surface
immunoglobulins of B cell lymphomas (Stevenson &
Stevenson, 1975) the specificity of targets is relative rather
than absolute and may well remain so. Yet some normal
tissues are not essential to life and some are highly proficient
at repairing damage. So we are blessed with a little latitude
in the matter of specificity. The antigen itself may be
secreted into the extracellular fluid compartment or mem-
brane bound, or intracellular. An intracellular location of
target site poses additional obstacles to access by antibody
vectors although intracellular localisation has been demon-
strated with keratin polypeptides as the antigen in perfused
breast cancer specimens (Dairkee & Hackett, 1988).
On the face of it a membrane bound target should be
advantageous compared with those secreted into the body
fluids. However, much of the targeting work reported in the
past decade has been directed at antigens which are secreted
in various amounts. The antigen-antibody encounter in body
fluids does not generally prevent antibody localisation unless
plasma antigen concentration is very high (Begent et al.,
1980; Searle et al., 1981).
Perhaps more important than the issue of whether the
target is membrane bound or secreted is that of antigen
density. This could be critical in determining the number of
antibody molecules retained at target sites (Capone et al.,
1984) and steric effects may operate at cell membranes. It is
possible that secreted antigens may be present in greater
profusion than those that are membrane bound since they
are distributed within the dimension of extra cellular space.
Various substances have augmented expression of tumour
associated antigens. These include butyrate (Chou et al.,
1977), glucorticoids (Wilson & Jawad, 1982) and cytotoxic
drugs (Browne & Bagshawe, 1982) which augmented
expression of human chorionic gonadotrophin; 5-bromo-2'-
deoxyuridine induced placental alkaline phosphatase (Chou
& Robinson, 1977) in trophoblastic cell lines, whilst
recombinant interferon increased the localisation in vivo of a
monoclonal antibody in mammary carcinoma xenograft
(Guadagni et al., 1988) and transforming growth factor p
induced CEA expression in human colon cancer cells
(Chakrabarty et al., 1988).
With membrane bound antigens there may be the pheno-
mena of modulation and capping in the presence of specific
bivalent antibody (Taylor et al., 1971). Demonstration of
these effects seems largely restricted to lymphoid cells and
polymorphonuclear leukocytes and its relevance to solid
tumours is uncertain. Capping has been inhibited by micro-
tubule acting agents including colchicine, vinblastine and
neocarcinostatin (Ebina et al., 1977). Avoidance of modula-
tion by the use of univalent antibodies (IgGFab/c) has been
demonstrated by Glennie & Stevenson (1982). Modulation,
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however, might be useful if endocytosis of the antibody-
toxin complex is required to achieve cytotoxicity.
Finally, there is the important characteristic of hetero-
geneity in antigen expression. At least one antigenic target,
human chorionic gonadotrophin (hCG) in choriocarcinoma,
is demonstrably a differentiation antigen virtually restricted
to the terminally differentiated syncytial cells (Hoshina et al.,
1983). Killing only the cells that synthesise HCG may simply
result in killing cells already programmed for death rather
than the clonogenic cytotrophoblastic cells. The most selec-
tive targets may therefore be differentiation markers.
Whereas some markers are expressed by a very high propor-
tion of cells in the neoplastic population (Glennie et al.,
1988), a marker such as CEA is generally expressed by a
much smaller fraction (Lewis et al., 1983). Thus the antibody
vector may only assemble on or around part of the target
population or as sometimes occurs in necrotic debris, so the
question how to attack the whole population from these
limited sites is central to overall strategy. The fact that
individual metastases may fail to express a particular target
antigen emphasises the point (Primus et al., 1983) and to
limit the constraints imposed by this heterogeneity multiple
targets and vectors may be required.
Antibody characteristics
If target specificity is less than absolute, antibody specificity
for the target is likely to be still less so. Monoclonal
antibodies confer epitope specificity and few, if any, fail to
find some binding sites in normal tissues, but clearly if
specific effects are to be obtained the binding ratio tumour/
critical non-tumour tissues, expressed as areas under the
curve, must be sufficiently favourable. Numerous strategies
have evolved in attempts to develop more specific antibodies
but in this matter serendipity still operates. However,
increasing their affinity and perhaps specificity through
peptide or other substitutions in antigen binding sites is now
an emerging possibility (Orlandi et al., 1986).
Immunoglobulin class and species of origin are highly
relevant if antibody alone is to be the effector molecule
achieving complement dependent cytotoxicity (Shouval et al.,
1982) or antibody directed cell cytotoxicity (Perez et al.,
1985) with specific human IgG isotypes.
There are also issues of molecular size, clearance, pene-
tration lipophilicity and dwell time. Antibody bound diva-
lently dissociated more slowly than that bound univalently
(Mason & Williams, 1980). Although Fab' has been shown
to penetrate spheroids better than F(ab')2 and F(ab')2 was
better than intact IgG (Sutherland et al., 1987), the situation
in vivo is undoubtedly more complex. Studies with Fab' have
shown rapid renal clearance of this molecule from plasma; it
is possible that infusion of Fab', or even smaller fragments
would show localisation in tumours but their efficiency in
terms of administered dose retained per gram of tumour
remains to be proven. Penetration of tumour masses is also
influenced by the diffusion characteristics of the molecule
and by tissue pressure. In the trade-off between tissue
penetration and renal clearance molecular size is important
but there may well be many other factors. Whether F(ab')2
or intact IgG localise best may also vary with the tumour
target. In one of our models F(ab')2 was superior to intact
IgG and in another the reverse was demonstrated. There
have been few studies with IgM as a vector; it would be
expected to localise slowly although its dwell time at tumour
sites may be prolonged. In all cases it may be necessary to
maintain a high concentration in plasma for several hours to
achieve maximum tumour localisation; the concentration of
antibody at tumour sites continues to increase so long as the
plasma concentration is higher than that in the tumour.
Clearance rate therefore appears to have an important role
in the localisation of antibody at target sites. If clearance is
very slow then normal tissues have prolonged exposure
which is dose limiting if the toxic agent is a radioisotope.
Our data suggest that secreted antigen tends to accelerate
clearance of the corresponding antibodies through immune
complex formation.
There has been much discussion about the binding affinity
of antibody in this context but no clear conclusion can yet
be drawn. The highest affinity may not necessarily be the
most suitable, particularly if the target antigen is secreted.
Cytotoxins
A variety of cell killing agents, notably cytotoxic drugs,
biotoxins such as ricin A chain (Thorpe et al., 1978) and
radioisotopes (Buchegger et al., 1988; Deguchi et al., 1986;
Ghose & Nigam, 1972), have been attached to antibodies
directed at tumour associated antigens and the limitations of
each approach can be recognised. Antibodies directed at
membrane bound antigens may be endocytosed but those
directed at secreted antigens are not likely to be and so are
unsuitable for cytotoxins that require an intracellular site of
action. Secreted antigens can however serve as targets for
radiation carrying antibodies.
Heterogeneity in antigen expression is a problem when
drug or toxin are bound to antibody. At any time only a
fraction of the cells constitute targets able to internalise the
cytotoxin. If antigen expression were cell cycle related it
would be expected that repeated treatments would provide
access to a greater fraction of the cancer cell population. In
the case of cytotoxic drugs release from the antibody into
extracellular space is a designable feature allowing diffusion
of small molecules to tumour inaccessible to antibodies.
However, the number of cytotoxic molecules required to
achieve a lethal effect may be very high and the number of
small cytotoxic molecules that can be attached to an IgG is
limited. Attempts to attach more than 13 methotrexate
molecules per antibody molecule have degraded the antibody
(Kanellos et al., 1985). Linker molecules or polymeric side
chains may allow this number to be increased but it may be
difficult to exceed the concentration of cytotoxic agents
delivered by conventional chemotherapeutic methods.
The obvious attraction of the biotoxins such as the ricin A
chain is that selective delivery of a relatively small number of
molecules per cell can prove lethal by inactivating the 60s
ribosomal subunit via nucleoside residues of 28s ribosomal
DNA (Endo & Tsurigi, 1987). The limiting factor again is
heterogeneity in target expression and the need for intra-
cellular localisation so that although there is the potential to
be effective against antigenically homogenous lymphomas
the potential of biotoxins for carcinomas in vivo remains to
be established.
Radioisotopes carried by antibodies address the issue of
heterogeneity essentially by localising within tumour masses
and engaging the total population through cross-fire effects.
Within the tumour mass the radiation sources are distributed
in a pattern determined by that of antigen distribution and
antibody penetration. If the target is a secreted antigen then
we cannot assume that the distribution of isotope as seen by
autoradiography is constant for any significant length of
time; the secreted antigen molecules are mobile and progress
toward the capillary system or lymphatics under the
influence of a complex array of kinetic effects (Jain &
Baxter, 1988).
The issue of microdosimetry from radioisotopes delivered
by antibodies is highly complex since it involves precise
distribution within the tumour, radiation energy, rate of
radiation delivery and cell proliferation kinetics. The major
factor however is that of the kinetics of distribution of the
antibodies in the body as a whole. With conventional
isotopes the total body radiation dose is greatest in the
period following administration and for some time total
body radiation exceeds selective radiation to tumour sites.
Only when other tissues and blood have been largely clearedCYTOTOXIC AGENTS AT CANCER SITES 277
of antibody does the radiation dose to tumour exceed that to
non-tumour sites. Bone marrow toxicity has ranged from
mild to fatal (Bucheger et al., 1988; Sharkey et al., 1988).
Areas under the curve for antibody in blood and tumour
illustrate the problem. Tumour to blood ratios can be
improved by accelerating clearance of antibody from blood
after tumour localisation has occurred (Begent et al., 1982;
Klibanoff et al., 1988). But 'cleared' antibody remains
radioactive in liver and spleen and contributes to the dose
received by non-target tissues including the urogenital tract.
It seems likely that the amounts of radioactivity required
to achieve tumoricidal doses will be high even when the
various components of the system are optimised substantially
beyond what has been achieved so far (Dykes et al., 1987).
The handling of large amounts of radioactive antibodies in
hospitals could also present formidable problems of staff
safety and waste disposal.
Uptake of radiolabelled anti-CEA antibodies has proved
to be highly variable between different patients and whilst
therapeutic effects have been achieved in the most favourable
cases (Begent et al., to be published) it is questionable
whether this approach can attain the desired level of general
applicability and acceptability.
Before we leave single stage systems there is of course the
question of using antibodies as cytotoxic agents in their own
right either through complement fixation (Shouval et al.,
1982) or through antibody directed cell mediated cyto-
toxicity. Heterogeneity of antigen expression might again be
a limiting factor but perhaps less so than with cytotoxics
that require endocytosis. Bispecific antibody constructs in
which one binding site is directed at the membrane bound
marker and the other at a T-cell marker have been made and
the potential of such constructs will no doubt be further
explored (Hale et al., 1983; Perez et al., 1985; Staerz &
Bevan, 1986; Clark & Waldmann, 1987).
Two stage systems
Recognition that the delivery and effector functions of a
selective pharmaceutical agent are distinct characteristics
leads us to the concept of the delivery component and the
effector component residing on separate molecules. In one
form, the delivery component would be given first, allowed
to localise and then used to capture an effector agent
injected later. In a second form the delivery component
carries an activating principle, typically an enzyme, which
can deplete an essential metabolite (Bagshawe, 1983; Searle
et al., 1986) or act on a natural substrate to produce a toxic
product or convert a subsequently administered prodrug into
an active form. The latter option allows delayed admini-
stration of the substrate until localisation of the enzyme to
tumour sites and clearance from normal tissues has occurred
so that catalytic action would occur predominantly at
tumour sites. This also incorporates the advantage that the
enzyme may act as an amplification system with each
localised antibody-enzyme catalysing the formation of many
active cytotoxic molecules from the less toxic prodrug.
Moreover, the cytotoxic molecules can be small and readily
diffusible capable of reaching cells in tumour masses that are
inaccessible to antibodies (Bagshawe, 1987; Bagshawe et al.,
1988).
We have called this approach antibody directed enzyme
prodrug therapy (ADEPT). By using an enzyme which has
no human analogue activation of the prodrug can be
restricted to those sites to which the enzyme is distributed by
the vector.
However, it has to be noted that following administration
of F(ab')2 antibody-enzyme conjugate, much of it remains in
the vascular compartment for several days and during this
time enzymic activity at tumour sites tends to diminish as
well as that in plasma. The conjugate is cleared more quickly
when the corresponding antigen is present in plasma and
immunoconjugates are formed. Because the plasma volume
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Figure 1 (a) Effect of galactosylation on clearance of
MABSB43. When the 1251I labelled anticarboxypeptidase
antibody SB43 was injected intravenously into tumour (LS174T)
bearing nude mice, 1251 persisted in the blood for many hours
and was detectable in the tumour. (b) When galactosylated 1251_
SB43 was given 125I activity in blood and tumour both fell
rapidly to very low levels.
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Figure 2 (a) Effect of MABSB43 on level of active drug in
tumour and tissues. Nude mice bearing LS174T tumour received
F(ab')2 anti-CEA GPG2 conjugate followed after 6 days by bis-
chloro aminobenzoyl glutamic acid. Mice were killed and tissues
extracted at the intervals shown for the measurement (HPLC) of
the active drug bis-chloro benzoic acid mustard. (b) Nude mice
were similarly treated to (a) but after 19h they received SB43
anti-CPG2 i.v. followed 1 h later by bis-chloro benzoic acid
mustard.
may greatly exceed tumour volume total plasma enzyme
activity may exceed that in tumour sites, even though the
concentration is lower. It is therefore necessary to wait until
plasma enzyme levels fall to very low values or alternatively
to clear the plasma of enzyme activity before giving the
prodrug.
Plasma clearance can be effected by means of a second
antibody directed at the enzyme or at the tumour localising
antibody (Sharma et al., to be published). It is important
however that clearing antibody should not significantly
reduce enzyme activity at tumour sites. We have studied
various techniques whereby this can be achieved including,
at the suggestion of G.T. Rogers, the introduction of an
appropriate number of galactose residues into an antibody.
This has been successfully applied to the second antibody.
Galactosylated second antibody still binds the antibody-
enzyme conjugate but undergoes rapid binding by hepatic
lectins and can rapidly clear the plasma of the enzyme of
antibody conjugate (Figure 1). Interference by the antibody
with the active site on the enzyme adds to the efficiency of
the clearance mechanism.278 K.D. BAGSHAWE
Studies in nude mice following plasma clearance show
favourable tumour to normal tissue ratios for the presence of
active drug (Figure 2). In contrast to the situation with
accelerated clearance of radiolabelled antibody where radio-
activity is increased in liver and spleen for some hours the
enzyme appears to be rapidly inactivated in the liver. A
possible problem is high uptake of the conjugate by macro-
phages in the lungs in our CC3 model. This may be related
to high levels of HCG in the mouse plasma resulting in
immunoconjugate formation and is a matter for further
study.
Prodrugs
The ADEPT approach requires a matching pair of enzyme
and prodrug. Starting with an active cytotoxic drug inactiv-
ation may be achieved by attaching an enzyme cleavable
moiety. A substantial array of cytotoxic drugs are potential
candidates for this approach. In the evolution of clinically
useful cytotoxic chemotherapy, agents have been chosen for
ability to show some evidence of selectivity as well as
cytotoxicity but a highly selective delivery system requires
only that the active drug be much more cytotoxic than the
prodrug from which it is generated. Alkylating agents are
non cell-cycle specific in cytotoxic action, diffuse well in
tissues, are equally toxic to well oxygenated and hypoxic
cells and tend not to show cross resistance so that, in high
enough concentration they are likely to be lethal to all cells
(see review by Frei et al., 1988). It was for these reasons that
we chose our first candidate drugs from this category,
although other classes of cytotoxic agent can also be
prepared in prodrug form.
The antibody based delivery system should ensure a highly
favourable concentration of active drug at tumour sites, even
though it will diffuse back into the blood and reach other
parts of the body in lower concentration. The first drugs to
be made for this approach have long half-lives but alkylating
agents with biological half-lives of only a few seconds have
been made (Cobb, 1967). Active drugs with a very short
half-life would substantially augment the effect of selective
distribution.
Enzyme
The primary consideration for the choice of enzyme is that it
should convert prodrug to active drug with high efficiency.
Ideally, a low concentration of enzyme should rapidly con-
vert a large number of substrate molecules. It should also be
an enzyme that is not present in the body including perhaps
the intestinal flora, although this would be surmountable by
intestinal sterilisation. Mammalian enzymes with no precise
human analogue may be usable but microorganisms are
likely to be a more fertile source. A conjugate with a human
enzyme has, however, been used in a xenograft model and
would have the attraction of low immunogenicity when used
in the human (Senter et al., 1988) but the presence of similar
enzyme in normal tissues is a potential limiting factor.
What has been achieved so far?
We showed that an enzyme, carboxypeptidase G2 which was
produced originally by PHLS Porton to catalyse metho-
trexate in cases of accidental overdose could be successfully
conjugated to an anti-hCG antibody (Searle et al., 1986).
The conjugate localised in choriocarcinoma xenografts and
retained catalytic activity. The next step was to identify an
alkylating agent that could be converted to a relatively inert
prodrug by addition of a glutamate prosthetic group. This
had to be done by a linkage cleavable by carboxypeptidase
COOH
Prodrug CICH2CH2, N
t1= 19.3h CCH2CH2 CONH -CH- CH2CH2COOH
CPG2conjugate Km =
4.9±0.4 F.M
Drug N CO t½/2 = 5.4h CICH2CH2
2 C(BOH
Figure 3 Action of carboxypeptidase on para-N-bis-(2-
chloroethyl)-aminobenzoyl glutamic acid.
Mono-Mesyl
CLCH2CH2\ C2H
/ CO-NH-CH
CH3SO3CH2CH2 CH2CH2CO2H
Para N-(mono-2-chloroethyl monomesyl)-aminobenzoyl
glutamic acid
Bis-Mesyl
CH3SO3CH2CH2\ /CO2H
N Q CO-NH-CH
CH3S03CH2CH2 CH2CH2CO2H
Para N-bis-(mesyl)-amino benzoyl glutamic acid
Figure 4 (a) Para N-(mono-2-chlorethyl monomesyl) glutamic
acid. (b) Para N-bis-(mesyl)-aminobenzoyl glutamic acid.
G2. A suitable bis-chlorobenzoic acid mustard (Figure 3)
was suggested by M. Jarman at the Institute of Cancer
Research and F. Searle. It was synthesised by C. Springer
who proposed two further developments of the original
compound (Figure 4).
The bis-chloro mustard was about 100-fold more cytotoxic
than its glutamated prodrug. In the absence of carboxy-
peptidase the prodrug hydrolysed to active drug very slowly
but enzyme or antibody-enzyme conjugate effected rapid
conversion.
The first two compounds have been undergoing pharma-
cokinetic and pharmacological testing against a chorio-
carcinoma xenograft (CC3). This xenograft secretes hCG and
has proved resistant to a variety of conventional
chemotherapeutic agents, even when given in maximum toler-
ated doses at weekly intervals. Growth delay occurred when
the anti-hCG-carboxypeptidase was followed 48-72h later
with the prodrug bis-chloro benzoic acid mustard. In some
cases a single treatment eradicated small tumours. With the
more active mono-mesyl, mono-chloro-benzoic acid mustard
consistent eradication of small established tumours was
achieved (Figure 5).
In a second tumour system, the colonic LS174T tumour,
the cells express carcinoembryonic antigen histochemically
but antigen is not detected in the plasma. In contrast to the
CC3 system where it proved possible to give the prodrug
48-72h after the antibody enzyme conjugate, the prodrug
could not be given in the LS174T model till 6 or 7 days after
the conjugate because enzyme persisting in the plasma
activated the prodrug with lethal effects. Giving a single
treatment with the bis-chloro benzoic acid mustard (3 doses
in 24h) produced no significant growth delay when given 6
days post-conjugate. The mono-mesyl mustard at 6 days
post-conjugate caused modest growth delay. This model
showed the necessity for a clearance system to eliminate
enzyme activity in the plasma as soon as peak enzyme levels
had been achieved in the tumour (Figure 6).
An anti-carboxypeptidase antibody (Sharma et al., to be
published) was found to inactivate the enzyme and when
galactosylated, clearance of enzyme activity from plasma was
achieved within a few minutes of giving the modified anti-
body. Prodrug could then be injected less than 24h afterCYTOTOXIC AGENTS AT CANCER SITES 279
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Figure 7 Effect of antibody-enzyme prodrug therapy on
S174T tumour. Mice bearing LS174T colon carcinoma xeno-
graft received anti-CEA CPG2 followed after 19h by galacto-
sylatedSB43 anti-CPG2 and1 h later received the first of three
10mg doses of monochloro monomesyl aminobenzoyl glutamic
acid. Growth delay was observed but tumour growth was
subsequently resumed.
ea a.ter .L z-)ln LIy .inre i.1 oses oI tne moocioro sustained in man for a period of several weeks providing at
mesyl aminobenzoyl glutamic acid and these are compared least a useful time window. This time window may be
he mean growth rate of untreated controls. adequate for early clinical trials using chemically bonded
Anti-HCG CPG2 CC3 rodent monoclonal antibody-enzyme conjugates and second
Prodrug antibody clearance systems. Monoclonal antibodies directed
I Prodrug at T-cell markers (Waldmann et al., 1988) or conjugated to
L , ,~ Y T,, daunorubicin (Durrant et al., 1989) may also be used to
inhibit the human anti-mouse response.
But it is necessary to look beyond such pilot studies. It is
Anti-CEA CPG2 LS 174T almost inconceivable that, assuming initial clinical trials
Prodrug prove encouraging, mouse monoclonals or fragments of
them, could be bonded to enzymes of microbial origin using
L |s I I T chemical conjugation methods on a scale adequate for
*tiCEA Cleaac general clinical use at an economic cost. So we must turn to
t- eaSB43 LS174T recombinant DNA technology for appropriate solutions. The
Prodrug DNA sequences for human immunoglobulins have been
J 0Prodrug spliced to those for the antigen binding site of mouse
y t fl t monoclonals (Morrison et al., 1984, 1988; Boulianne et al.,
o 1 2 3 4 5 6 7 1987; Reichmann et al., 1988a,b). Such chimaeric anti- D
1 2 3 4 5 6 7 bodies appear on present evidence to have low immuno-
Days genicity and the murine component may be reduced to parts
6 Protocols used in preliminary treatment of CC3 and of the hypervariable region of the light and heavy chains
IT xenograft bearing mice (a) mice bearing CC3 chorio- that form the antigen binding site itself.
oma xenografts received anti-hCG carboxypeptidase and It has also proved possible to produce chimaeras of
odrug was administered between 52 and 76 hours (b) in immunoglobulin and an enzyme (Neuberger et a!., 1984). FT bearing mice the prodrug could not be given until 67 Thus we can see a stage in development in which the ost anti-CEA CPG2. (c) Using the clearing antibody SB43 aTibody con of a s geindetlyopntrce anibody-
ig was given 24h post anti-CEA CPG2. antibody component of a genetically constructed antibody-
enzyme complex has low immunogenicity. But what about
the antibody enzyme conjugate and marked growth the enzyme?
)ccurred after a single treatment consisting of one dose There are techniques which might be used to reduce the
body-enzyme conjugate and 3 doses of prodrug within immunogenicity of a microbial enzyme such as the attach-
'igure 7). ment of polyethylene glycol (Abuchowski et al., 1981) which
it has been claimed (Wilkinson et al., 1987) can induce
immune tolerance to foreign proteins. However, it has also
esponse and macromolecular reconstruction been shown that antibodies raised to synthetic analogs of an
esterolytic transition state have catalytic activity, so-called
ating human cancer xenografts growing in nude mice 'ABzymes' (Pollack et al., 1986; Lerner & Tramontano,
thing, treating metastatic cancer successfully in man is 1987). The modification of antigen binding sites to achieve
r. A pre-requisite for antibody based targeting in man specific functions therefore appears possible. Perhaps it is no
rge amount of a consistent product made possible by longer fanciful to anticipate molecules which combine target
lonal technology. Human monoclonals have proved binding capability with catalytic function and low immuno-
and in our xenograft systems an immune response to genicity in man. Such molecules have the potential for
monoclonals would not be a limiting factor to production by eukaryotes or prokaryotes on a clinically
d treatment although an antibody response to relevant scale but their development for a wide range of
ial enzymes probably would be. tumours is likely to take years to achieve.
ooking ahead to clinical application it is already Finally, if we have non-immunogenic tumour seeking
;hed that antibody responses readily develop to mouse enzymes, what happens to the second antibody clearance
lonal antibodies and may be anti-idiotypic (Rowe et mechanism? The antigen binding sites and enzyme active site
35). It has been shown both in the rabbit (Ledermann would still be targets for second, humanised and galacto-
1988a) and in man (Ledermann et al., 1988b) that sylated antibodies or alternatively the genetically engineered
vosuppression with cyclosporin can inhibit host anti- molecules could be optimized to achieve both tumour
response to murine monoclonals. Inhibition can be localisation and plasma clearance.
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It isn't possible to predict how far genetic engineering will
be able to achieve these macromolecular reconstructions but
no insurmountable problems have yet been defined so we
may continue to live hopefully. This is not to suggest that
the ADEPT approach has no limitations. Antibody uptake
in relative terms tends to diminish as tumours enlarge (Pedley
et al., 1987), so we may have doubts about its effectiveness
against large tumour masses. There is also the question of
whether the blood/brain barrier can be circumvented.
(Begent, 1985; Richardson et al., 1986). Local accumulations
of enzyme activity could be a limiting factor through
immunoconjugate deposition at non-tumour sites. In the
choriocarcinoma model both radiolabelled anti-hCG (Searle
et al., 1981) and anti-hCG-enzyme conjugates have shown
high levels in lung tissue, probably due to accumulation in
lung macrophages. Lung damage and fibrosis would be
potentially serious limiting factors. A further concern is the
marker-less cell with clonogenic potential in isolation at sites
distant from marker expressing cells. Clearly, such cells are
likely to escape any antibody based attack which provides
cytotoxic effects for only a few hours. Perhaps those cells
will be susceptible if the cytotoxic effect is sustained for
several days or if it is delivered repeatedly, but here I am
plunging into deep speculation. Studies with metastasising
tumour models may show how important this could be and
whether effective strategies can be evolved.
However, there is no reason on present evidence to close
on a pessimistic note. A wide repertoire of monoclonal
antibodies with interesting specificities continues to emerge.
Prodrugs from which can be generated active drugs several
orders of magnitude more potent than those we have so far
tested will be synthesised. The development of matching
pairs of enzymes and prodrugs with improved characteristics
presents a considerable but not an unrealistic challenge and
it seems possible that a whole new field of therapy will
emerge.
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